Acelrx Pharmaceuticals Inc Zukünftige P/E
Was ist das Zukünftige P/E von Acelrx Pharmaceuticals Inc?
Zukünftige P/E von Acelrx Pharmaceuticals Inc ist -0.27
Was ist die Definition von Zukünftige P/E?
Das Terminkurs-Gewinn-Verhältnis ist das Verhältnis des Aktienkurses eines Unternehmens zum geschätzten Gewinn des Unternehmens für die nächsten zwölf Monate.
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
Zukünftige P/E von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Acelrx Pharmaceuticals Inc
Was macht Acelrx Pharmaceuticals Inc?
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Unternehmen mit zukünftige p/e ähnlich Acelrx Pharmaceuticals Inc
- Brickell Biotech Inc hat Zukünftige P/E von -0.34
- Unity Biotechnology Inc hat Zukünftige P/E von -0.32
- SenesTech Inc hat Zukünftige P/E von -0.31
- Bluebird bio Inc hat Zukünftige P/E von -0.29
- Adlabs Entertainment hat Zukünftige P/E von -0.27
- Génomic Vision SA hat Zukünftige P/E von -0.27
- Acelrx Pharmaceuticals Inc hat Zukünftige P/E von -0.27
- Tonix Pharmaceuticals Corp hat Zukünftige P/E von -0.26
- SINTX Technologies Inc hat Zukünftige P/E von -0.26
- MSP Steel & Power hat Zukünftige P/E von -0.24
- Just Inc hat Zukünftige P/E von -0.22
- Idea Cellular hat Zukünftige P/E von -0.20
- Idea Cellular hat Zukünftige P/E von -0.19